Please assess the completion status of the following clinical trial:

Trial Title: Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants must have ulcerative colitis or Crohn's disease with low grade dysplasia or polyploid dysplasia or have a history of dysplasia and increased positive beta-catenin levels confirmed by a consensus of the study pathologists (2 of 2, or 2 of 3)~* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1~* Absolute neutrophil count (ANC) \> 1,500/uL~* Platelets \> 100,000/uL~* Total bilirubin within normal institutional limits~* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\]/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\] =\< 1.5 times upper limit of normal~* Creatinine within normal institutional limits~* International normalized ratio (INR) \< 1.5~* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of baseline pregnancy test, throughout the duration of the study, and for 1 month following cessation of study drug; females must begin adequate contraception immediately following screening pregnancy test; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately; if she is pregnant, she will be immediately withdrawn from the study and followed until the birth of the child~* Ability to understand and the willingness to sign a written informed consent document~Exclusion Criteria:~* Subjects with life-threatening medical conditions that would preclude study treatment intervention and colonoscopy~* Participants may not be receiving any other investigational agents~* History of allergic reactions to rice or compounds of similar chemical or biologic composition to myo-inositol (i.e., urticaria, dermatologic reaction)~* Use of medications known to elevate serum blood glucose; participants on steroids are still eligible, as they will be monitored weekly for fasting blood glucose~* Participants with dysplasia-associated lesion or mass (DALM), high-grade dysplasia or invasive colonic carcinoma are excluded~* Uncontrolled intercurrent illness including, but not limited to~  * Ongoing or active infection~ * Symptomatic congestive heart failure~ * Unstable angina pectoris~ * Cardiac arrhythmia~ * Chronic renal failure~ * Chronic renal insufficiency~ * Psychiatric illness or social situations that would limit compliance with study requirements~* Prior treatment with myo-inositol~* History of systemic chemotherapy within 18 months of screening~* Subjects taking valproic acid and/or lithium~* Diabetes mellitus~* History of total proctocolectomy~* Concomitant primary sclerosing cholangitis (PSC)~* Pregnant or lactating subjects are excluded

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (inositol) (Type: EXPERIMENTAL): Beginning within 14 days after colonoscopy, patients receive inositol PO QD on days 1-14 and BID on days 15-90.
- Arm II (placebo) (Type: PLACEBO_COMPARATOR): Beginning within 14 days after colonoscopy, patients receive placebo PO QD on days 1-14 and BID on days 15-90.

Based on this trial design, predict the completion outcome and termination type (if applicable).